Novoteris recently announced that the FDA has granted orphan drug designation for inhaled nitric oxide therapy.

The pilot trial demonstrated an 8.8% absolute improvement from baseline. Phase 2 trials are planned for 2014.

Click on the title to read more

Advertisements